Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lonza
Pharma
Takeda, AZ-Daiichi, Fosun-Henlius—Fierce Pharma Asia
Takeda's R&D chief explained his new investment priorities. AZ and Daiichi's TROP2 ADC cleared the FDA. Fosun failed to buy out Henlius. And more.
Angus Liu
Jan 24, 2025 8:55am
CDMO Joinn wraps up purchase of Lonza biologics plant in China
Jan 23, 2025 9:45am
Sales up 23% for Korean CDMO powerhouse Samsung Biologics
Jan 22, 2025 11:41am
Roche-Innovent, AstraZeneca, Viatris and more—Fierce Pharma Asia
Jan 3, 2025 8:37am
Lonza aims to shed capsules business, restructure CDMO offerings
Dec 12, 2024 8:58am
Swiss CDMO Lonza widens its ADC digs with 2028 expansion
Nov 12, 2024 10:00am
